HR-1300-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Neal Dunn (R-FL)
What it does
This bill would require private health insurance plans to cover prostate-specific antigen (PSA) screening and other evidence-based preventive care for prostate cancer for men age 40 and older who are at high risk of developing the disease — for example, those with a family history of prostate cancer. Coverage would have to be provided without any cost-sharing (no copays, deductibles, or coinsurance). It applies to screenings not already mandated under U.S. Preventive Services Task Force (USPSTF) recommendations.
Who benefits
High-risk men age 40 and older — particularly Black men (who have roughly twice the prostate cancer incidence rate of white men) and men with a first-degree relative diagnosed with prostate cancer, both of whom are considered high-risk. Oncologists, urologists, and diagnostic labs that perform PSA tests and follow-up procedures. Early-stage prostate cancer patients who may avoid more costly and invasive late-stage treatment. Insurers and employers who may see reduced long-term treatment costs if early detection prevents advanced-stage cases.
Who is hurt
Private health insurers and self-insured employers who would bear the direct cost of the newly mandated coverage. Employers and workers in plans subject to the mandate may see modest premium increases to offset those costs. Men not covered by private insurance — including those on Medicaid, Medicare, or uninsured — would not benefit, potentially widening disparities in access. Competing preventive care programs may face indirect resource pressure if insurers tighten other coverage to offset costs.
Supporters argue
Supporters argue that the USPSTF currently recommends PSA screening only for men ages 55–69, leaving high-risk men under 55 without guaranteed no-cost coverage despite facing significantly elevated risk. They contend that Black men are disproportionately affected — diagnosed at younger ages and with more aggressive disease — and that closing this coverage gap directly addresses a documented racial health disparity. Early detection through PSA screening, they argue, reduces the likelihood of late-stage diagnosis, which carries far higher mortality and treatment costs.
Opponents argue
Opponents argue that the USPSTF's age-based recommendations reflect careful weighing of PSA screening's known harms — including false positives, unnecessary biopsies, and overtreatment of slow-growing cancers that may never cause symptoms. They contend that mandating coverage beyond USPSTF guidelines could drive overdiagnosis and overtreatment, exposing patients to harm without clear net benefit. Critics also argue that federal mandates on private insurance add to premium costs for all enrollees, and that targeted outreach and shared decision-making, rather than blanket coverage mandates, are a more evidence-consistent approach.
Constitutional context
Congress regulates private health insurance under the Commerce Clause (Art. I, §8, cl. 3) and the Taxing and Spending Clause (Art. I, §8, cl. 1). NFIB v. Sebelius (2012) affirmed broad congressional authority to regulate existing commercial activity in insurance markets. Post-Loper Bright (2024), any agency rules implementing this mandate would face independent judicial review rather than automatic deference, meaning the scope of "high-risk" definitions or coverage standards set by regulators could be subject to challenge.
Checks and balances
Congress gains authority to set private insurance coverage standards; HHS and relevant agencies would implement and enforce the mandate through rulemaking, subject to independent judicial review under Loper Bright (2024).
Historical precedent
The ACA (2010) established the framework of requiring private insurers to cover USPSTF-recommended preventive services without cost-sharing; this bill extends that model to a population not currently covered by USPSTF recommendations.